Premium
A Call for a Consortium for Optimal Management of Drug–Drug Interactions in Patient Care
Author(s) -
Burger DM,
Smolders EJ,
Schapiro J,
Drenth JPH,
Back DJ
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.648
Subject(s) - drug , drug development , risk analysis (engineering) , intensive care medicine , medicine , business , pharmacology , product (mathematics) , geometry , mathematics
During clinical development of medicines, manufacturers are obliged to assess the risk of drug–drug interactions (DDIs) with their new drug. There is no doubt that product labels of drugs that are nowadays introduced to the market contain much more information on DDIs than in the past. Indeed, the drug label is often the first source for DDIs available to physicians and pharmacists. But how informative are the data presented in the drug labels?